S7 Crohn's Disease: What to Do After Antitumour Necrosis Factor-α Therapy Fails?

According to Montreal classification, 3 vedolizumab patients had ileal disease and 12 had ileocolonic disease; 3 patients had nonstricturing, nonpenetrating disease, 8 had stricturing and 4 penetrating disease. Ustekinumab and vedolizumab are commonly used for the treatment of Crohn's disease (CD) after antitumour necrosis factor- (anti-TNF- ) therapy fails. Considering the Montreal classification, 14 ustekinumab patients had ileal disease, 2 had colonic and 21 ileocolonic disease; 10 patients had nonstricturing, nonpenetrating disease, 15 had stricturing and 12 penetrating disease. [Extracted from the article]